Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?

Anja Strangfeld; Maria Eveslage; Matthias Schneider; H. J. Bergerhausen; T. Klopsch; A. Zink; Joachim Listing

doi:10.1136/ard.2011.151043

Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?

著者: Anja Strangfeld, Maria Eveslage, Matthias Schneider, H. J. Bergerhausen, T. Klopsch, A. Zink, Joachim Listing - Annals of the Rheumatic Diseases 2011 被引用: 362

Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? | Litlas